Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACI-24.060 in Prodromal Alzheimer's Disease and Down Syndrome (ABATE)
NCT05462106Phase 2Recruiting
- Sponsor
- AC Immune SA
- Start
- Jun 2022
- Primary completion
- Apr 2029
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of ACI-24 in Alzheimer's disease (AD) (11 arms), sponsored by AC Immune SA. Primary endpoints: Adverse Events at 100 weeks, Abnormal MRI results at 100 weeks and 3 more. Started Jun 2022; status: recruiting.
02
Drugs
ACI-24
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05462106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05462106.